Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Description Statussort icon Initial Date
<a href="/venture-capital/all-companies/visterra-inc">Visterra, Inc.</a> Discovering and developing innovative products that will transform the prevention and treatment of infectious diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/mascoma-corporation">Mascoma Corporation</a> Leading technology for the conversion of biomass to fuels and chemicals. Private 2006 View Profile
<a href="/venture-capital/all-companies/moderna">Moderna</a> Pioneering an entirely new drug modality using messenger RNA therapeutics™. Private 2010 View Profile
<a href="/venture-capital/all-companies/ensemble-therapeutics-corporation">Ensemble Therapeutics Corporation</a> Deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”. Private 2004 View Profile
<a href="/venture-capital/all-companies/quanterix-corporation">Quanterix Corporation</a> Developing ground-breaking tools in high definition diagnostics. Private 2007 View Profile
<a href="/venture-capital/all-companies/seahorse-bioscience-inc">Seahorse Bioscience, Inc.</a> XF instruments are the industry standard in cellular bioenergetic measurements. Private 2001 View Profile
<a href="/venture-capital/all-companies/selventa">Selventa</a> Pioneering the development of Systems Diagnostics (SysDx™). Private 2001 View Profile
<a href="/venture-capital/all-companies/medidametrics-inc">MedidaMETRICS, Inc.</a> Developing activity-based costing systems for healthcare providers. Private 2010 View Profile
<a href="/venture-capital/all-companies/pronutria">Pronutria</a> Transforming medicine with ProNutrein™ products, protein nutrients identified in the human diet, for the dietary management of disease. Private 2010 View Profile
<a href="/venture-capital/all-companies/seres-health">Seres Health</a> Discovering and developing Ecobiotic® therapeutic products to treat important diseases by targeting the underlying biology of the human microbiome. Private 2012 View Profile
<a href="/venture-capital/all-companies/midori-renewables-inc">Midori Renewables Inc.</a> Deploying Breaking the Biomass Barrier™ technology that melts and digests biomass into sugars. Private 2009 View Profile
<a href="/venture-capital/all-companies/blend-therapeutics-inc">Blend Therapeutics Inc.</a> Discovering new classes of medicines that have unique modes of action to result in drugs with differentiated therapeutic properties. Private 2012 View Profile
<a href="/venture-capital/all-companies/tangent-medical-technologies-inc">Tangent Medical Technologies Inc.</a> Developing and commercializing IV therapy products. Private 2011 View Profile
<a href="/venture-capital/all-companies/syros-pharmaceuticals-0">Syros Pharmaceuticals</a> Harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Private 2012 View Profile
<a href="/venture-capital/all-companies/ecosense-lighting%C2%AE">EcoSense Lighting®</a> Providing best-in-class LED lighting solutions for use in architectural applications. Private 2013 View Profile
<a href="/venture-capital/all-companies/editas-medicine">Editas Medicine</a> Unlocking the promise of genome editing to deliver life-changing medicines. Private 2013 View Profile